

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1759R1

Serial No.

09/589,395

Applicant

Ashkenazi et al.

Filing Date


07 Jun 2000

Group

1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
GN	1	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	2	870,827	14.10.98	EPO				
	3	WO 97/01633	16.01.97	PCT				
	4	WO 97/25428	17.07.97	PCT				
	5	WO 97/46686	11.12.97	PCT				
	6	WO 98/18921	07.05.98	PCT				
	7	WO 98/28426	02.07.98	PCT				
	8	WO 98/32856	30.07.98	PCT				
	9	WO 98/35986	20.08.98	PCT				
	10	WO 98/39361	11.09.98	PCT				
	11	WO 98/41629	24.09.98	PCT	—	—		
	12	WO 98/46643	22.10.98	PCT				
	13	WO 98/46751	22.10.98	PCT				
	14	WO 98/51793	19.11.98	PCT	—	—		
	15	WO 99/02653	21.01.99	PCT				
	16	WO 99/04001	28.01.99	PCT				
	17	WO 99/07738	18.02.99	PCT				
	18	WO 99/09165	25.02.99	PCT	—	—		
	19	WO 99/11791	11.03.99	PCT				
	20	WO 99/33980	08.07.99	PCT				

RECEIVED

DEC 29 2000

TECH CENTER 1500/2500

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

21	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
22	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40" <u>Nature</u> 357(6373):80-82 (1992)
23	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)
24	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5381):1305-1308 (1998)
25	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
26	Ashkenazi et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand" <u>Journal of Clinical Investigation</u> 104(2):155-162 (1999)
27	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
28	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)

Examiner

Gur Raut

Date Considered

11/02/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1759R1

Serial No.

09/589,395

Applicant

Ashkenazi et al.

Filing Date

07 Jun 2000

Group

1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

29	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
30	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
31	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
32	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
33	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
34	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
35	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)
36	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
37	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)
38	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL" <u>Journal of Biological Chemistry</u> 273(23):14363-14367 (1998)
39	Gliniak and Le, "Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo is Enhanced by the Chemoptherapeutic Agent CPT-11" <u>Cancer Research</u> 59:6153-6158 (1999)
40	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol</u> 7:R750-R753 (1997)
41	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
42	Gras et al., "BCMAP: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes" <u>Int. Immunology</u> 7:1093-1106 (1995)
43	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
44	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth" <u>Journal of Experimental Medicine</u> 188(6):1185-1190 (1998)
45	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
46	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
47	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)
48	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)

Examiner

Date Considered

11/02/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1759R1

Serial No.

09/589,395

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

07 Jun 2000

Group

1646

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)


49	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
50	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
51	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
52	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
53	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma" <u>EMBO Journal</u> 11:3897-3904 (1992)
54	Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed" <u>Nucleic Acids Research</u> 22:1147-1154 (1994)
55	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
56	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
57	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family" <u>J. Leukocyte Biol.</u> 60:1-7 (1996)
58	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
59	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations" <u>Journal of Experimental Medicine</u> 190:1697-1710 (1999)
60	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily" <u>Int. Immunology</u> 10:1693-1702 (1998)
61	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
62	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
63	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
64	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
65	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
66	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
67	Mongkolsapaya et al., "Cutting Edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 160(1):3-6 (1998)
68	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)

Examiner

Date Considered

11/02/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1759R1	Serial No. 09/589,395
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 07 Jun 2000	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
69	Moore et al., "BLYS: member of the tumor necrosis factor family and B lymphocyte stimulator" <u>Science</u> 285(5425):260-263 (1999)				
70	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, and c-Jun NH ₂ -Terminal Kinase" <u>Journal of Biological Chemistry</u> 274:15978-15981 (1999)				
71	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)				
72	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)				
73	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(12):6216-6221 (1997)				
74	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)				
75	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)				
76	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor" <u>FEBS Letters</u> 431(3):351-356 (1998)				
77	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)				
78	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling" <u>FEBS Letters</u> 424(1-2):41-45 (1998)				
79	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer" <u>Nature</u> 396(6712):699-703 (1998)				
80	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)				
81	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)				
82	Renshaw et al., "Humoral Immune Responses in CD40 Ligand-deficient Mice" <u>Journal of Experimental Medicine</u> 180:1889-1900 (1994)				
83	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)				
84	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)				
85	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" <u>Journal of Experimental Medicine</u> 189:1747-1756 (1999)				
86	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)				
87	Scholtissek and Grosse, "A plasmid vector system for the expression of a triprotein consisting of β -galactosidase, a collagenase recognition site and a foreign gene product" <u>Gene</u> 62:55-64 (1988)				
88	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)				
Examiner 				Date Considered 11/02/01	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1759R1

Serial No.

09/589,395

Applicant

Ashkenazi et al.

Filing Date

07 Jun 2000

Group

1646


LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

89	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
90	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
91	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens" <u>J. Leukocyte Biol.</u> 65:680-683 (1999)
92	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
93	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
94	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
95	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
96	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
97	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
98	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
99	Verma et al., "Rel/NF- κ B/I κ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
100	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
101	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
102	Walczak et al., "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo" <u>Nature Med.</u> 5:157-163 (1999)
103	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
104	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (1997)
105	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)
106	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)

Examiner



Date Considered

11/02/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.